NVCT — Nuvectis Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $216.17m
- $184.54m
Annual cashflow statement for Nuvectis Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.9 | -19.1 | -22.3 | -19 | -26.4 |
| Non-Cash Items | 1.89 | 1.71 | 4.71 | 4.86 | 6.03 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.49 | 3.82 | 1.6 | 1.9 | 4.4 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -9.5 | -13.6 | -16 | -12.2 | -16 |
| Other Investing Cash Flow Items | 0 | 0 | — | 0 | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | 0 | — | 0 | — |
| Financing Cash Flow Items | — | -4.07 | -1.39 | -0.382 | 29.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 15.2 | 27.8 | 15.1 | 11.7 | 29.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.74 | 14.3 | -0.867 | -0.593 | 13.1 |